# Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

> **NCT03663764** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 57 (estimated)

## Conditions studied

- Thymoma and Thymic Carcinoma

## Interventions

- **DRUG:** Thymosin a1
- **RADIATION:** hypofractionated radiotherapy
- **DRUG:** concurrent chemoradiotherapy

## Key facts

- **NCT ID:** NCT03663764
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-13
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663764, "Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03663764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*